Abstract
We report the discovery and SAR of two novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs). Exploration of several structural features in the western and eastern part of the imidazopyrimidinone core and combinations thereof, revealed compound 4a as a mGlu5 PAM with good in vitro potency and efficacy, acceptable drug metabolism and pharmacokinetic (DMPK) properties and in vivo efficacy in an amphetamine-based model of psychosis. However, the presence of CNS-mediated adverse effects in preclinical species precluded any further in vivo evaluation.
Keywords:
Dihydroimidazopyrimidinone; Imidazopyrimidinone; Metabotropic glutamate receptor 5 (mGlu(5)); Positive allosteric modulator (PAM); Schizophrenia.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Allosteric Regulation
-
Animals
-
Antipsychotic Agents / chemical synthesis
-
Antipsychotic Agents / chemistry*
-
Antipsychotic Agents / pharmacokinetics
-
Brain / metabolism
-
Drug Evaluation, Preclinical
-
Half-Life
-
Heterocyclic Compounds, 2-Ring / chemical synthesis
-
Heterocyclic Compounds, 2-Ring / chemistry*
-
Heterocyclic Compounds, 2-Ring / pharmacokinetics
-
Humans
-
Imidazoles / chemical synthesis
-
Imidazoles / chemistry*
-
Imidazoles / pharmacokinetics
-
Locomotion / drug effects
-
Microsomes, Liver / metabolism
-
Protein Binding
-
Pyrimidinones / chemical synthesis
-
Pyrimidinones / chemistry*
-
Pyrimidinones / pharmacokinetics
-
Rats
-
Receptor, Metabotropic Glutamate 5 / chemistry*
-
Receptor, Metabotropic Glutamate 5 / metabolism
-
Structure-Activity Relationship
Substances
-
Antipsychotic Agents
-
Heterocyclic Compounds, 2-Ring
-
Imidazoles
-
Pyrimidinones
-
Receptor, Metabotropic Glutamate 5
-
imidazole